Precision medicine is increasingly defined by how early disease can be detected—and how intelligently risk can be stratified. Tempus AI, Inc. (NASDAQ: TEM) has announced a collaboration with Median Technologies (EPA: ALMDT) to integrate Median’s eyonis® LCS into the Tempus Pixel platform, expanding AI-powered lung cancer screening capabilities across the U.S.
The move brings together two AI-driven imaging portfolios at a time when lung cancer screening rates remain critically low.
Addressing a Screening Gap with AI
According to research from the American Cancer Society, only about 20% of eligible individuals in the United States were screened for lung cancer in 2024. The organization estimates that full participation among eligible individuals could prevent more than 62,000 lung cancer deaths over five years.
eyonis® LCS is an AI-based CADe/CADx software as a medical device (SaMD) designed for lung cancer screening. It enables clinicians to:
- Detect lung nodules
- Characterize nodules
- Risk-stratify lesions
- Generate malignancy scoring
All from a single CT scan—without requiring additional workflow steps.
Earlier this month, eyonis® LCS received 510(k) clearance from the U.S. Food and Drug Administration, clearing the path for broader clinical deployment.
Integration into Tempus Pixel
The collaboration will embed eyonis® LCS into Tempus Pixel, Tempus’ FDA-cleared and CE-marked AI-enabled radiology platform.
Tempus Pixel provides:
- Advanced lesion analysis tools
- Automated reporting
- Quantification and tracking of radiological findings
With eyonis® LCS integrated, radiologists will be able to non-invasively characterize CT-identified lung nodules at the moment of detection using a proprietary malignancy score. This feature is designed to help clinical teams stratify patients and prioritize follow-up care within lung cancer screening programs.
In high-volume radiology settings, risk-based prioritization can be critical—especially as imaging backlogs and workforce constraints persist nationwide.
Strategic Fit Within Tempus’ AI Ecosystem
The collaboration builds on Tempus’ broader imaging and diagnostics strategy.
In 2022, Tempus acquired Arterys, incorporating AI tools across lung CT, chest X-ray, and cardiac MRI workflows. It later acquired Paige, adding nearly 7 million clinically annotated, de-identified pathology slides to its dataset.
Together, these acquisitions have strengthened Tempus’ radiology-pathology integration capabilities—an increasingly important frontier in precision medicine.
By combining imaging AI, molecular data, and large-scale clinical datasets, Tempus aims to move beyond detection toward predictive, personalized disease management.
Why This Matters for Lung Cancer Care
Lung cancer remains the leading cause of cancer-related death globally, largely because it is often diagnosed at later stages.
Low-dose CT screening has been shown to reduce mortality, but uptake remains limited due to access barriers, awareness gaps, and workflow burdens.
AI tools like eyonis® LCS may address part of that challenge by:
- Increasing diagnostic confidence
- Reducing variability in nodule interpretation
- Streamlining radiology workflows
- Supporting earlier intervention decisions
Importantly, embedding AI directly into existing radiology systems—as opposed to adding standalone tools—reduces friction and supports real-world adoption.
The Bigger Picture: AI in Preventive Oncology
Healthcare AI is increasingly shifting from retrospective analysis to proactive disease interception.
In oncology, that shift means earlier detection, better triage, and risk-informed management strategies. By integrating FDA-cleared lung screening AI into a national-scale imaging platform, Tempus and Median are positioning themselves at the intersection of diagnostic automation and preventive precision care.
As screening participation expands—and if AI-driven triage proves to improve efficiency and outcomes—such integrations could meaningfully influence lung cancer mortality trends in the years ahead
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
